Welcome to our dedicated page for LEXICON PHARMACEUTICALS SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexicon Pharmaceuticals, Inc. filings document a biopharmaceutical issuer with common stock listed on The Nasdaq Capital Market under LXRX. Its regulatory record includes Form 8-K reports on operating and financial results, clinical and regulatory updates, material agreements, debt financing, equity offerings and conversions of preferred stock into common stock.
Proxy and governance filings describe director elections, executive compensation, equity incentive plans and shareholder voting matters. Registration and prospectus-related disclosures address common-stock issuance programs, capital structure and public-market financing alongside the company's development programs in cardiometabolic and neurologic disease areas.
Lexicon Pharmaceuticals updated investors on its cash position, fundraising plans and late-stage pipeline. The company ended 2025 with unaudited cash, investments and restricted cash of $125.2 million, which it believes is sufficient to support planned operations into 2027, subject to final audit.
Lexicon achieved a $10 million milestone payment in January under its Novo Nordisk licensing agreement and may earn up to an additional $20 million in milestones in 2026. The company launched an underwritten public offering of common stock and plans a concurrent private placement to an affiliate of Invus, L.P., its largest stockholder.
The SONATA pivotal Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy is targeting 500 patients, with enrollment completion anticipated in mid-2026 and topline results expected in the first quarter of 2027. The FDA raised no objections to advancing pilavapadin into Phase 3 for diabetic peripheral neuropathic pain, and pooled Phase 2 data showed a two-point average daily pain score reduction at 12 weeks with the 10 mg dose. FDA feedback also indicated that the investigator‑initiated STENO1 study of sotagliflozin may provide sufficient safety data to support a potential resubmission of the ZYNQUISTA NDA in type 1 diabetes in 2026.
Lexicon Pharmaceuticals plans an underwritten public offering of common stock, together with a concurrent private placement to an affiliate of its largest shareholder, Invus, L.P., at the same price as the public deal. The Invus affiliate may instead receive convertible preferred shares if authorized common shares are insufficient, with those preferred shares expected to convert into common stock after shareholder approval of additional authorized shares.
Lexicon expects to use net proceeds from the offering and private placement to fund research and development of its drug candidates, including sotagliflozin and pilavapadin, and for working capital and general corporate purposes. The company recently reported unaudited year-end 2025 cash, investments and restricted cash of $125.2 million and a $10 million milestone from its Novo Nordisk licensing agreement, with the potential for up to $20 million in additional milestones in 2026, which it believes can support planned operations into 2027. As of January 26, 2026, Lexicon had 363,466,277 common shares outstanding, and Invus and its affiliates held approximately 49.7%, giving them significant influence over governance and capital decisions.
Lexicon Pharmaceuticals (LXRX) filed a prospectus supplement tied to its Open Market Sale Agreement with Jefferies, covering potential at‑the‑market sales of common stock with an aggregate sales price of up to $75,000,000 under its effective Form S‑3 shelf. The supplement relates to the shelf registration filed on August 2, 2024 and declared effective on August 15, 2024.
The company also corrected an inadvertent statement in the supplement that suggested Ernst & Young LLP audited the effectiveness of internal control over financial reporting as of December 31, 2024. As a smaller reporting company and non‑accelerated filer, Lexicon is exempt from that requirement, and EY did not perform such an audit. The notice does not constitute an offer or solicitation in jurisdictions where it would be unlawful.
Lexicon Pharmaceuticals launched an at-the-market offering of up to $75,000,000 of common stock through Jefferies as sales agent. No sales have been made to date. Jefferies will receive a 3.0% commission on gross proceeds, and net proceeds will be used to fund research and development and for working capital and general corporate purposes.
An affiliate of Invus, L.P., the company’s largest stockholder, may concurrently purchase shares to maintain its proportionate ownership in connection with sales under the program, but only after yearly issuances under the ATM exceed two percent of shares outstanding as of the prior December 31. Any such purchases would occur in a concurrent private placement at the same price as the public sales.
The common stock trades on Nasdaq as “LXRX.” The last reported sale price was $1.38 per share on November 5, 2025. Shares outstanding were 363,398,860 as of November 5, 2025; this is a baseline figure, not the amount being offered.
Lexicon Pharmaceuticals (LXRX) filed a prospectus supplement for an at-the-market (ATM) offering of up to $75,000,000 of common stock under its existing Form S-3, with Jefferies LLC as sales agent. The Shares may be offered and sold from time to time pursuant to the Open Market Sale Agreement.
As of November 6, 2025, no sales have been made pursuant to the Agreement. Vinson & Elkins L.L.P. provided a legal opinion on the validity of the Shares, filed as Exhibit 5.1.
Lexicon Pharmaceuticals (LXRX) filed its Q3 2025 10‑Q, reporting total revenues of $14.2 million, driven largely by $13.2 million in licensing revenue from its Novo Nordisk agreement. Net product revenue from INPEFA® was $1.0 million. The company posted a net loss of $12.8 million, a substantial improvement from a loss of $64.8 million a year ago, as operating expenses fell sharply following late‑2024 restructuring.
Cash, cash equivalents, restricted cash and short‑term investments totaled $145.0 million as of September 30, 2025, including $29.0 million in restricted cash tied to debt covenants. Lexicon repaid $45.0 million on its Oxford term loans in April, leaving $56.5 million in long‑term debt (carrying value) and a weighted average interest rate of 11.8%. The Novo Nordisk license delivered $40.7 million in year‑to‑date licensing revenue; $4.3 million of the $45.0 million upfront remained as deferred revenue at quarter‑end. The company maintains a $75 million at‑the‑market equity program available.
Lexicon Pharmaceuticals, Inc. furnished a Form 8-K to disclose that it issued a press release reporting financial results for the quarter ended September 30, 2025.
The press release is provided as Exhibit 99.1 and the company states that the information in this report and the exhibit is being furnished under Item 2.02 for results of operations and financial condition, rather than filed for purposes of Exchange Act liability or incorporation by reference.